,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['db04']
my thoughts on db04 for discussion: - sequencing of therapy. - bystander effect or additional her2 target mechanism? - better test than ihc to identify her2 low? - it will likely pan-out to all her2 low cancers! #asco2022 #asco22 
???????? ?? ??????? - ?????? ???????? Medical Oncologist #breastcancer. MD Anderson Alumni “All tweets are my own and RT?endorsement”